SENP6 and Burkitt lymphoma: We also identified SENP6 deletions in a broad range of BCL sub-entities, including marginal zone (4.2%), mantle cell (7.7%), follicular (15.6%), and Burkitt lymphoma (6.5%), indicating a possible role of SENP6 or the SUMOylation pathway in other lymphomas (Supplementary Fig. 3d).